ZEPOSIA\u00ae is the commercial brand name of Ozanimod Hydrochloride Capsules, an orally active sphingosine-1-phosphate (S1P) receptor modulator developed by Bristol Myers Squibb. It selectively binds to S1P1 and S1P5 receptors on lymphocytes, traps lymphocytes within lymph nodes and limits their migration into the central nervous system, so as to restrain autoimmune inflammatory damage in multiple sclerosis.<\/p>\n\n\n\n
Main Indications<\/strong> Common Side Effects<\/strong> Approval Status in China<\/strong> Buy ZEPOSIA (Ozanimod Hydrochloride Capsules)\u00a0online from China and save up to 80% on costs . no insurance needed . compare prices from a certified HongKong pharmacy .with fast shipping. Contact us now on WhatsApp to get the latest prices.<\/p>\n\n\n\n <\/p>\n","protected":false},"excerpt":{"rendered":" ZEPOSIA\u00ae is the commercial brand name of Ozanimod Hydrochloride Capsules, an orally active sphingosine-1-phosphate (S1P) receptor modulator developed by Bristol Myers Squibb. It selectively binds to S1P1 and S1P5 receptors on lymphocytes, traps lymphocytes within lymph nodes and limits their migration into the central nervous system, so as to restrain autoimmune inflammatory damage in multiple […]<\/p>\n","protected":false},"author":4,"featured_media":3434,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[101],"tags":[],"class_list":["post-3433","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-drug-news"],"blocksy_meta":[],"yoast_head":"\n
Treatment of adult patients with relapsing multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting multiple sclerosis and active secondary progressive multiple sclerosis.<\/p>\n\n\n\n
Common mild adverse reactions: Upper respiratory tract infection, elevated liver transaminase, bradycardia, diarrhea, fatigue, nausea and lumbago.
Laboratory abnormalities: Peripheral lymphopenia, increased hepatic enzyme and creatinine.
Severe manageable risks: Severe bradycardia\/AV block, systemic severe infection, clinical hepatotoxicity and macular edema.<\/p>\n\n\n\n
ZEPOSIA\u00ae (domestic trade name: Hotpecia, Ozanimod Hydrochloride Capsules, 0.92mg) obtained official marketing approval in China in 2023. It is a prescription drug waiting for inclusion in China\u2019s Category B medical insurance list.<\/p>\n\n\n\n